Rocket Doctor AI (AIDR) Q1 2026 earnings summary

Executive summary

• Q1 2026 revenue was $737,103, up 5.7% QoQ; U.S. in-network access expanded to ~21 million insured lives across California, New York and Maryland.

• Completed U.S. patient visits rose 283% QoQ, from 177 to 678; Q1 Canada visits increased ~25% YoY to 47,790.

• Growth reflects payer network expansion, higher patient activity and platform scaling, while most projected revenue from new payer agreements remained unrealized in Q1.

Financial highlights

• Revenue was $737,103 in Q1 2026, up 5.7% from Q4 2025 and 39.3% from Q3 2025 revenue of $529,123.

• Gross margin was 75%, versus 84% in Q4 2025 and 88% in Q3 2025; increased variable costs and revenue mix contributed to the decline.

• Net comprehensive loss attributable to equity holders was $4.646 million, versus $2.147 million in Q1 2025; basic and diluted loss per share was $0.05 versus $0.04.

• Adjusted EBITDA loss was $2.89 million, compared with $2.1 million in Q4 2025 and $1.8 million in Q3 2025.

• Cash and cash equivalents were $3.5 million at March 31, 2026, versus $641,779 at December 31, 2025.

Outlook and guidance

• Approximately 21 million insured lives across three U.S. states provide a runway for growth; less than 3% of projected revenue associated with newly finalized payer agreements was reflected in current financials.

• Further payer-contract growth, targeted marketing and patient-acquisition spending are expected to support core financial metrics through the rest of FY2026.

• April U.S. visits rose 69% month on month to ~1,200; May volumes were projected to continue the growth trend.

• Priorities include multi-state expansion, B2B SaaS and white-label offerings, and AI workflow automation intended to reduce administrative costs and support margin expansion.